secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016253
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q2 net loss $15.1M; cash $125.6M funds into 2024; TSC-101 IND cleared
---------------------------------------------------------------------------

- Net loss $15.1M vs $10.7M in prior-year quarter; revenue $4.1M (up from $2.8M) on Novartis collaboration.
- Cash and equivalents $125.6M (plus $5M restricted); runway into 2024.
- FDA cleared IND for TSC-101 (HA-2) for HCT relapse prevention; Phase 1 umbrella trial now enrolling.
- Debora Barton, M.D., appointed Chief Medical Officer; brings cell therapy and oncology R&D experience.
- Plans to file INDs for solid-tumor candidates TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017022016253/0000950170-22-016253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017022016253/tcrx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer